RxDoctor Payments Data

Amy Mathers, MD

Infectious Disease · Charlottesville, VANPI 1821025107

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $14,554 of the $21,385 with a category attached, or 68.1%. 8 manufacturers reported payments, led by Merck at 26.2% of the total. Reporting peaked in 2024 at $6,643 and has fallen 99.2% since, to $53 in 2025. Among infectious disease clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$21,385in general payments, 2019–2025

Across 16 payments — averaging $1336.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$6K
  • Biomerieux Inc$4K
  • Cepheid$3K
  • Beckman Coulter, Inc.$2K
  • Accelerate Diagnostics Inc.$2K
  • Melinta Therapeutics, LLC$2K
  • plus $3K from 2 others

What the payments were for

  • Consulting fees$14,55468%
  • Speaking & faculty fees$5,74027%
  • Travel & lodging$9034%
  • Food & beverage$1881%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck3$5,610
Biomerieux Inc3$4,496
Cepheid1$2,500
Beckman Coulter, Inc.1$2,200
Accelerate Diagnostics Inc.2$2,094
Melinta Therapeutics, LLC1$1,925
Life Technologies Corporation1$1,400
Shionogi Inc4$1,160

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,385 in reported general payments places this provider in the 95th percentile of 194 infectious disease providers in Virginia.

See all infectious disease providers in Virginia

Medicare billing

Part B allowed, 2024
$24,920
Medicare patients
78
Services billed
268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other infectious disease in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →